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Abstract
Background: ABO-incompatible live transplantation (ILT) is not occasionally performed due to a relative high risk of graft
failure. Knowledge of both graft and patient survival rate after ILT is essential for donor selection and therapeutic strategy.
We systematically reviewed studies containing outcomes after ILT compared to that after ABO-compatible liver
transplantation (CLT).
Methodology/Principal Findings: We carried out a comprehensive search strategy on MEDLINE (1966–July 2010), EMBASE
(1980–July 2010), Biosis Preview (1969–July 2010), Science Citation Index (1981–July 2010), Cochrane Database of
Systematic Reviews (Cochrane Library, issue 7, 2010) and the National Institute of Health (July 2010). Two reviewers
independently assessed the quality of each study and abstracted outcome data. Fourteen eligible studies were included
which came from various medical centers all over the world. Meta-analysis results showed that no significantly statistical
difference was found in pediatric graft survival rate, pediatric and adult patient survival rate between ILT and CLT group. In
adult subgroup, the graft survival rate after ILT was significantly lower than that after CLT. The value of totally pooled OR
was 0.64 (0.55, 0.74), 0.92 (0.62, 1.38) for graft survival rate and patient survival rate respectively. The whole complication
incidence (including acute rejection and biliary complication) after ILT was higher than that after CLT, as the value of totally
pooled OR was 3.02 (1.33, 6.85). Similarly, in acute rejection subgroup, the value of OR was 2.02 (1.01, 4.02). However, it was
4.08 (0.90, 18.51) in biliary complication subgroup.
Conclusions/Significance: In our view, pediatric ILT has not been a contraindication anymore due to a similar graft and
patient survival rate between ILT and CLT group. Though adult graft survival rate is not so satisfactory, ILT is undoubtedly
life-saving under exigent condition. Most studies included in our analysis are observational researches. Larger scale of
researches and Randomized-Control Studies are still needed.
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Introduction
ABO-incompatible liver transplantation was regarded as a
relative contraindication because of high incidence of bile duct and
vascular complications. In the early stage, the graft failure rate was
unacceptably 50% due to humoral rejection [1,2,3,4]. Currently,
there is a great shortage of liver donors all over the world. The
number of patients in the waiting list is always multiple times of the
number of liver donors. To lessen humoral rejection, a variety of
strategies have been tried, including plasmapheresis, hepatic
perfusion, various immunosuppressive agents, steroids, Rituximab
and splenectomy [5,6]. Particularly in recent years, advanced new
immunosuppressive agents are developed, patient and graft
survival rate after ILT has increased dramatically. However, high
risk of complication after ILT, such as biliary complication[7],
acute rejection[6,8,9] and hepatic artery thrombosis, is still a vital
issue related to ILT.
To our knowledge, no systematic evaluation has been
performed on graft/patient survival rate or complication inci-
dence. The objective of this study was to summarize different
outcomes between ILT and CLT group. Clarifying the graft/
patient survival rate and complication incidence between two
groups may give a new protocol for liver transplantation when
different ABO blood type is taken into account.
Methods
Ethics
All included data were from the published literature and there
was no ethical approval required.
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To identify published and unpublished reports of relevant
studies, we searched relevant electronic databases, including
MEDLINE (1966–July 2010), EMBASE (1980–July 2010), Biosis
Preview (1969–July 2010), Science Citation Index (1981–July
2010), Cochrane Database of Systematic Reviews (Cochrane
Library, issue 7, 2010).We also searched for unpublished trials and
those in progress using repositories of clinical trials, including the
National Institute of Health (July 2010). Google Scholar was also
used to find fulltexts. The websites of European Liver Transplant
Registry (ELTR), Scientific Registry of Transplant Recipients
(SRTR) and China Liver Transplant Registry (CLTR) were
researched for additional information. Searches were not restricted
by year of publication in Chinese or English. The search strategy
included the terms ‘‘ABO* AND liver transplantation*’’. Refer-
ence lists of all studies included were scanned to identify additional
potentially relevant studies. Two reviewers independently screened
the titles and abstracts of identified papers, and most potentially
relevant studies’ full text copies were obtained.
ABO-incompatible liver transplantation include the following
donor to recipient pairings: A to B,O; B to A,O; AB to A,B,O.
Other pairings (including identical pairings) are considered ABO-
compatible. Biliary complications include biliary leakage and
stricture after liver transplantation. Clinical rejection is defined as
an increase in the liver enzymes with corresponding liver biopsy or
response to increased drug dose (immunosuppressive or steroids)
without liver biopsy.
Selection
We conducted this systematic review and meta-analysis
according to a prespecified protocol, which was guided by the
Meta-analysis of Observational Studies in Epidemiology consensus
statement [10] and the PRISMA Statement [11]. Those studies
which had a comparison between ILT and CLT group in graft
survival rate, patient survival rate or complication incidence met
our criteria.
Validity assessment
Because of the ethic limitations, it is hard to perform a
randomized controlled trial on this topic. All of the studies
included in this research were observational studies.
Data Abstraction
Two reviewers(SYY,XFX)independently evaluated each cita-
tion and abstracted information, disagreements were resolved by
discussion. Another review (JW) independently confirmed the
accuracy of all abstracted data. To quantify the level of agreement
between reviewers, a k statistic was calculated. The k statistic is a
chance-corrected proportional index, with values ranging from +1
(perfect agreement) to 21 (complete disagreement).The mean
value of k fell into the range of 0.75–1.00 was viewed as high
agreement. For all included studies, we abstract the following data
from original publications: first author and year of publication;
country; target population; study size; 1-,3-,5-,10-year graft
survival rate and patient survival rate; acute rejection incidence
and biliary complication incidence.
Statistical Analysis
We drew information from each accordant article. If necessary
data was not showed directly in the article, we attempted to
contact authors to get original data (but failed to get useful
information), and a data extraction software-Engauge Digitizer
(Free Software Foundation, Boston, US) was also used to get
details. The meta-analysis was done consists with recommenda-
tions from the Cochrane Collaboration and the PRISMA
Statement [11] with standard software (Revman 5.0 and Stata
version 10.0).
Quantitative data synthesis
Heterogeneity was assessed with I
2 statistics [12]. I
2 is the
proportion of total variation across studies that is due to
heterogeneity rather than chance (sampling error). I
2 values of
25%, 50% and 75% respectively represents the cut off line of low,
moderate and high heterogeneity [13].Odds ratio (OR) was used
as the summary statistic to perform statistical analysis of
dichotomous variables. A fixed-effect model was used for
calculations of summary estimates and their 95% CI. However,
when the heterogeneity was high (I
2.50%), a random-effects
model was used. A p value of less than 0.05 was considered to
indicate statistically significant difference. Sensitivity analysis was
performed using the method of excluding extreme data (the
maximum or the minimum). We used Egger test (Stata version
10.0) to examine the potential risk of publication bias. Publication
bias was indicated when p value was less than 0.10.
Results
Flow of included studies
We screened 3401 citations, from which 413 abstracts are used
for further assessment (Fig. 1). Twenty-nine articles met our
criteria. Sixteen were subsequently excluded because they did not
contain the detail what we exactly need. Thus, we finally identified
fourteen articles to assess patient/graft survival rate as well as
incidence of various complications after ILT. However, they were
all observational studies without random or control. After
adjustment for chance concerning the agreement between
reviewers, the k coefficient on the agreement of the included
studies was 0.83 (0.95 CI 0.77–0.89), showing good agreement
between reviewers in data extraction.
Study Characteristics
The 14 [1,2,8,14,15,16,17,18,19,20,21,22,23,24] studies were
published from 1990 to 2009. The characteristics are presented in
Table 1. Thirteen were English and 1 was Chinese (Yang et al.).
The studies were from 10 countries: 5 studies from the America, 3
from Japan, 1 from Canada, 1 from Australia, 1 from China, 1 from
Belgium, 1 from France and 1 study from Nordic countries
(Norway, Sweden, Denmark, Finland). All the results of Meta-
analysis were showed in Table 2.
Graft and Patient Survival rate
We analyzed the graft survival rate between ILT group and
CLT group according to different age range. The totally pooled
OR was 0.64 (0.55, 0.74) (Random-effects model). This result was
statistically significant (p,0.05) (Fig. 2). Egger test did not indicate
obvious publication bias (p=0.904) (Fig. 3). Further more, patient
survival rate was also collected for analysis. The totally pooled OR
was 0.92 (0.62, 1.38) (Fig. 4). This result was not statistically
significant (p=0.70) (Random-effects model). Egger test did not
indicate obvious publication bias (p=0.925) (Fig. 5).
One-year graft survival rate
There were 5 studies contained the 1-year graft survival rate
between two groups including all aged cases. Among the 5 articles,
the study of Stewart et al. contained the most cases, in which 831
patients received ABO-incompatible liver transplantation, and
there were 2818 patients accepted ABO-compatible liver trans-
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were much smaller, they totally contained 43, 234, 70 and 36 cases
respectively. The test of homogeneity showed that results were
heterogeneous across studies (p=0.004, I
2=74%) and a random-
effects model was used. Meta-analysis showed the pooled OR was
0.30 (0.12, 0.75). This result was statistically significant (p,0.05).
Sensitivity analysis was also performed, it owned a low sensitivity.
The result of pediatric 1-year graft survival rate is based on
another 4 studies: the study of Stewart et al., Ueda et al., Heffron
et al., and Cacciarelli et al.. The study size was respectively 464,
568, 138, and 144. This group of study size was much more
balanced. The test of homogeneity showed that results were
coherent across studies (p=0.46, I
2=0.0%) and a fixed-effects
model was used. Meta-analysis showed the pooled OR was 0.83
(0.59,1.17). This result was not statistically significant (p=0.28). A
low sensitivity was presented after performing sensitivity analysis.
There were 3 studies contained the information about adult 1-
year graft survival rate. They were study of Stewart et al., Toso et
al. and Cacciarelli et al.. Their study size was 2340, 108 and 229
respectively. The test of homogeneity showed that results were
coherent across studies (p=0.76, I
2=0.0%). So we used a fixed-
effects model. Meta-analysis showed the pooled OR was 0.6 (0.50,
0.73). This result was statistically significant (p,0.05). However,
this subgroup showed a high sensitivity after performing sensitivity
analysis.
One-year patient survival rate
The result of patient 1-year survival rate was based on 7 studies.
They were Heffron et al., Toso et al., Chui et al., Reding et al.,
BJØRO et al., Gugenheim et al. and Caccuarelli et al.. Their
study size swayed from 43–234. The test of homogeneity showed
that results were coherent across studies (p=0.33, I
2=13%).
Meta-analysis showed the pooled OR was 0.87 (0.52, 1.46). This
result was not statistically significant (p=0.59). A low sensitivity
was presented after performing sensitivity analysis.
Three-year graft survival rate
There were 3 studies provided 3-year graft survival rate on
pediatric liver transplantation between ILT and CLT groups.
They were Heffron et al., Stewart et al., and Cacciarelli et al., and
their study size were 17, 227 and 28 respectively. The test of
homogeneity showed that results were coherent across studies
(p=0.81, I
2=0.0%). Meta-analysis showed the pooled OR was
0.96 (0.64, 1.43). This result was not statistically significant
(p=0.84). A low sensitivity was presented after performing
sensitivity analysis.
The result of graft 3-year survival rate about adult was based on
2 studies. They were Stewart et al., BJØRO et al., and their study
Figure 1. Flow of included studies.
doi:10.1371/journal.pone.0016521.g001
Table 1. Characteristics of included studies.
Study Country Publication population No. of ILT/CLT
Yang (14) China 2007 All ages 21/45
Toso (15) Canada 2007 Adult 14/94
Ueda (16) Japan 2006 Pediatric 74/494
Heffron (17) US 2010 Pediatric 12/21
Heffron (8) US 2006 Pediatric 16/122
Chui (18) Australia 1997 All ages 7/36
Cacciarelli (19) US 1995 Pediatric 14/130
Sanchez (20) US 1993 All ages 7/36
Reding (21) Belgium 1992 All ages 16/54
BJØRO (22) Nordic 2003 Adult 10/219
Tokunaga.(23) Japan 1993 Pediatric 3/31
Iwamoto (24) Japan 2008 Adult 15/37
Gugenheim (2) France 1990 All ages 17/217
Stewart (1) US 2009 Infant 130/390
Pediatric 116/348
Adult 585/1755
doi:10.1371/journal.pone.0016521.t001
Outcomes of ABO-Incompatible Liver Transplantation
PLoS ONE | www.plosone.org 3 January 2011 | Volume 6 | Issue 1 | e16521size were 1153 and 151. The test of homogeneity showed that
results were coherent across studies (p=0.22, I
2=35%). Meta-
analysis showed the pooled OR was 0.46 (0.38, 0.55). This result
was statistically significant (p,0.05). A low sensitivity was
presented after performing sensitivity analysis.
Three-year patient survival rate
The result of patient 3-year survival rate was based on 2 studies.
They were BJØRO et al., and Caccuarelli et al., and their study
size were 160 and 109. The test of homogeneity showed that
results were coherent across studies (p=0.8, I
2=0.0%). Meta-
analysis showed the pooled OR was 0.62 (0.24, 1.59). This result
was not statistically significant (p=0.32). A low sensitivity was
showed.
Five-year graft survival rate
There were 2 studies provided 5-year graft survival rate on
pediatric liver transplantation between ILT and CLT groups.
They were Stewart et al., and Toso et al., and their study size were
respectively 220 and 406. The test of homogeneity showed that
results were coherent across studies (p=0.29, I
2=9%). Meta-
analysis showed the pooled OR was 0.75 (0.53, 1.06). This result
was not statistically significant (p=0.1). A low sensitivity was
presented.
The result of graft 5-year survival rate about adult was based on
3 studies. They were Stewart et al., Toso et al., and BJØRO et al.,
and their study size were 1076, 55, and 129. The test of
homogeneity showed that results were coherent across studies
(p=0.43, I
2=0.0%). We used a random-effects model. Meta-
analysis showed the pooled OR was 0.68 (0.56, 0.81). This result
was statistically significant (p,0.05). However, a relatively high
sensitivity was showed in this subgroup.
Five-year patient survival rate
The result of patient 5-year survival rate was based on 3 studies.
They were Toso et al.,and BJØRO et al., and their study size were
58, and 219. The test of homogeneity showed that results were
coherent among the included studies. We used a fixed-effects
model. Meta-analysis showed the pooled OR was 1.52 (0.61, 3.79).
This result was not statistically significant (p=0.37) and showed a
low sensitivity.
Ten-year graft survival rate
The result of graft 10-year survival rate on pediatric was based
on 2 studies. The study of Stewart et al., and Ueda et al., and their
study size were 199 and 377. The test of homogeneity showed that
results were heterogeneous among the included studies. We used a
random-effects model. Meta-analysis showed the pooled OR was
0.73 (0.39, 1.25). This result was not statistically significant
(p=0.06). The adult 10-year graft survival rate was based on only
1 study.
Complications
Several complications after liver transplantation were searched
and evaluated, we finally selected acute rejection and biliary
complication for analysis. We used a random-effects model for
meta analysis. The totally pooled OR of complication was 3.02
(1.33, 6.85) (Fig. 6), which suggested that the whole complication
incidence after ILT was higher than that after CLT. This result
was statistically significant (p=0.018). Sensitivity analysis and
Table 2. Meta-analysis results.
Outcomes
Number of
studies Number of participants Test of homogeneity OR(95% CI) P value
CLT ILT I
2(%) P value
Graft survival
1-y All ages 5 2818 889 74 0.004 0.30(0.12,0.75) 0.00
Pediatric 4 1094 220 0.0 0.46 0.83(0.59,1.17) 0.28
Adult 3 2601 872 0.0 0.76 0.60(0.50,0.73) 0.00
3-y Pediatric 3 506 146 0.0 0.81 0.96(0.64,1.43) 0.84
Adult 2 1974 695 35 0.22 0.46(0.38,0.55) 0.00
5-y Pediatric 2 842 190 9 9 0.29 0.75(0.53,1.06) 0.10
Adult 3 2068 609 0.0 0.43 0.68(0.56,0.81) 0.00
10-y Pediatric 2 842 190 67 0.08 0.73(0.39,1.25)
a 0.06
a
Total(95%CI) 12016 3531 39 0.08 0.73(0.39,1.25)
a 0.00
a
Patient survival
1-y 7 872 94 13 0.33 0.87(0.52,1.46)
a 0.59
a
3-y 2 349 24 0.0 0.80 0.62(0.24,1.59) 0.32
5-y 2 459 24 0.0 0.38 1.52(0.61,3.79) 0.37
Total(95%CI) 1463 125 0.0 0.53 1.02(0.66,1.58) 0.93
Complications
Biliary complication 4 222 70 80 0.002 0.35(0.06,2.14)
a 0.25
a
Acute rejection 4 216 58 53 0.09 1.23(0.38,4.04)
a 0.76
a
Total(95%CI) 438 128 73 0.00 0.64(0.22,1.89)
a 0.42
a
aRandom-effects model.
doi:10.1371/journal.pone.0016521.t002
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observed (p=0.711).
Biliary complication
The result of biliary complication incidence was based on 4
studies (Fig. 6). The study of Iwamoto et al., Yang et al., Heffron et
al., and Sanchez-Urdazpal et al., and their study size were 52, 66,
137, and 36. The test of homogeneity showed that results were
heterogeneous among the included studies. We used a random-
effects model. Meta-analysis showed the pooled OR was 4.08
(0.90, 18.51). A low sensitivity was presented after performing
sensitivity analysis.
Acute rejection
There were also 4 studies included in this group for analysis
(Fig. 6). The study of Yang et al., Heffron et al., Tokunaga et al.,
and Sanchez-Urdazpal et al., and their study size were 66, 137, 34,
and 36. The test of homogeneity showed that results were
homogeneous among the included studies. We used a fixed-effects
model. Meta-analysis showed the pooled OR was 2.02 (1.01, 4.02).
A low sensitivity was presented after performing sensitivity
analysis.
Discussion
We comprehensively reviewed the literature on survival rate
and complication outcomes of ABO-incompatible liver transplan-
tation. Analysis was mainly performed in pediatric and adult
subgroups, infant subgroup analysis was not included in our
research due to insufficient data. Our meta-analysis results showed
that there was no statistically significant difference in pediatric
graft survival rate no matter 1-year, 3-year, 5-year, and 10-year
graft survival rate. However, the 1-year, 3-year, and 5-year graft
survival rate on adult had statistical difference between ILT and
CLT group. The graft survival rate of CLT group surpassed that
of ILT group. The 1-year, 3-year, and 5-year patient survival rate
was not statistically different. The patient survival rate after ILT
was elevated mainly by retransplantation. When it comes to
complication, no statistical difference was demonstrated by our
results on neither acute rejection nor biliary complication. ABO-
incompatible liver transplantation might not be a high risk factor
of complication after liver transplantation.
ABO-incompatible liver transplantation was considered inap-
propriate because of its theoretically high risk of humoral rejection.
Early efforts showed that organ loss and patient death with graft
failureratesfrom30%tomorethan50%,and nearlyhalfoftheILT
patients ultimately requiring retransplantation. According to
previous studies, age played an important role in the development
of allograft failure [25,26]and younger recipients turned better
outcomes after ILT [27]. Egawa et al. indicated that the patient
survival rate after ILT gradually decreased with the rise of
recipients’ age. The 5-year patient survival rate was 85% in infants
and only 52% in adults[28]. Moreover, Heffron demonstrated that
the 1-year actual graft survival rate (92.3%) after ILT is higher than
that after CLT (83.4%) utilizing standard immunosuppression with
selective postoperative plasmapheresis[8]. Our meta-analysis results
confirmed that pediatric graft survival rate after ILT liver
transplantation was not obviously different from that of CLT group
though we did not analyze the detail for infant. On the other hand,
adult graft survival rate after ILT was much lower. Several reasons
may accounted for this phenomenon: first, anti-A and anti-B
antibody titers remain at low levels at early age because of its
incomplete capacity of immune system [29]. Second, the comple-
ment system was not so sensitive compared to adults [30].
Recipients’ age plays an important role in prognosis after liver
transplantation. According to the data of ELTR, children’s survival
rate was much higher than adults’. Similarly, the result of ABO-
incompatible liver transplantation in adult seemed more serious.
Our results showed that the graft survival rate of adult after ILTwas
obviously lower than after CLT.
Acute rejection, biliary complication as well as infection mainly
accounted for graft failure after ILT. Antibodies that against the
Figure 3. Egger test results of studies on graft survival rate.
doi:10.1371/journal.pone.0016521.g003
Figure 2. Meta-analysis results of graft survival rate.
doi:10.1371/journal.pone.0016521.g002
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doi:10.1371/journal.pone.0016521.g005
Figure 4. Meta-analysis results of patient survival rate.
doi:10.1371/journal.pone.0016521.g004
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lium, inducing complement fixation, endothelial damage and the
formation of platelet thrombi which followed by the clotting
cascade, causing hemorrhagic necrosis. In early failed ILT grafts,
pathologic examination showed widespread areas of geographic
hemorrhagic necrosis, antibody and complement components
were deposited in arteriole [31]. Except antibody-mediated
rejection, acute rejection also contains T cell-mediated rejection.
They two always appear at the same time when acute rejection
occurs [32]. The graft had been assumed to be resistant to
antibody-mediated rejection in ABO-compatible liver transplan-
tation[33],we believe that antibody-mediated rejection plays a
more important role in ILT than in CLT. Immunological lesions
in arteriole always lead to lethal biliary complication such as
ischemic cholangitis, also called ischemic-type biliary lesion
(ITBL). The dominant feature of ischemic cholangitis is biliary
stricture[34]. Most ischemic stricture patients need retransplanta-
tion [35].
According to the study of Sanchez-Urdazpal, biliary complica-
tion and rejection incidence after ILT was much higher than that
after CLT [20]. Our results showed that the whole complication
incidence and acute rejection incidence after ILT were higher
than that after CLT. Though biliary complication incidence after
ILT was on the increase compared to that after CLT, it did not
Figure 6. Meta-analysis results of complication incidence.
doi:10.1371/journal.pone.0016521.g006
Figure 7. Egger test results of studies on complication incidence.
doi:10.1371/journal.pone.0016521.g007
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18.51). One explanation is that the number of studies included
in biliary complication subgroup was relatively small. Another
factor is that authors were reluctant to report their high com-
plication incidence results, and willing to share their successful
experience. Several reports indicated that administration of ritu-
ximab and plasmapheresis before transplantation can reduce the
incidence of antibody-mediated rejection both in DDLT and
LDLT[36,37].Using the therapeutic regimen of perioperative
plasmapheresis, intrahepatic arterial infusion, splenectomy, and
triple- or quadruple-drug therapy containing calcineurin inhibitor,
steroid, and cyclophosphamide, azathioprine, or MMF, the
survival rate after ILT has been promoted greatly. Hanto reported
that there was no immunological graft loss using total plasma
exchange, splenectomy, and quadruple immunosuppression
[6,38,39,40].
Limitations
To our knowledge, this is the first comprehensive review of this
topic. We believe our search strategy was sufficient and included
all relevant articles. Several reviewers attended to identify all these
articles and we used subgroup analysis, which minimized potential
selection biases and ensured accuracy of the abstracted data. Our
systematic review has several limitations. First, there was no
randomized studies on our topic, all of them were observational
studies. And there was only one article clearly stated its match-
control method in collecting its original data. Second, the number
of included studies and participants in each subgroup analysis was
relatively small. Third, some subgroups (1-year adult graft survival
rate, 5-year adult graft survival rate, 5-year patient survival rate)
had relatively high sensitivity, which was mainly caused by the
relatively larger study size from the study of Stewart. It was a
national registry analysis from the United States. However, we
failed to get similar registry reports from other Europe or Asia.
Otherwise, the analysis result might be more comprehensive and
representative. The meta-analysis results of these three subgroups
should be carefully concluded. Fortunately, it did not affect the
pooled results of total graft survival rate and patient survival rate.
In order to get convinced results, more large scale of statistical data
and Randomized-Control Study should be needed. Fourth, we did
a mixed analysis and did not differentiate LDLT or DDLT.
Because most studies only had mixed results and the information
in each group was insufficient for analysis. Fifth, potential bias has
several considerations: included studies were non-randomized
researches; the study sizes were relatively small; the relatively high
heterogeneity among studies; some subgroups included only a few
studies; chance related bias.
In conclusion, ABO-incompatible liver transplantation is still an
inferior selection due to its relatively low graft survival rate though
therapeutic strategy for ILT has been improved recently. ILT in
pediatric is feasible because patient/graft survival rate is no
obviously difference compared to CLT. Pediatric ILT has not
been a contraindication anymore. Though adult graft survival rate
is not so satisfactory, ILT is undoubtedly being viewed as a vital
option for patients with acute liver failure requiring exigent liver
transplantation. In addition, adult patient survival rate and
complication incidence are still acceptable due to retransplanta-
tion. However, some larger scale of researches and Randomized-
Control Studies are still needed on ABO-incompatible liver
transplantation.
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